A large variety of 2 billion heparin!

On December 24, Qianhong Pharmaceutical issued an announcement stating that the company's enoxaparin sodium injection passed the consistency evaluation and was the second domestic company to pass the evaluation

Enoxaparin sodium injection is a low-molecular-weight heparin, which is mainly used for the treatment of symptoms such as anticoagulation and antithrombosis, and for the prevention and treatment of thrombosis or embolic diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.

According to data from Meinnet.

Sales of terminal enoxaparin sodium injection in public medical institutions in China (unit: ten thousand yuan)

Source: Mi Nei.

For a long time, the domestic enoxaparin sodium injection market has been dominated by the original manufacturer Sanofi, with a market share of more than 50%

In addition to the original manufacturer Sanofi, there are currently 8 enoxaparin sodium injection manufacturers in the domestic market, but only two companies have passed the consistency evaluation, namely Hai Purui and Qianhong Pharmaceutical

Data source: Mi Neiwang database